Halozyme Therapeutics | HALO - Capital Y Las Reservas





Capital Y Las Reservas Cambio Fecha
Acadia Pharmaceuticals USD 1.31B 58.54M 2026-06
Agios Pharmaceuticals USD 1.03B 83.09M 2026-06
Alnylam Pharmaceuticals USD 1.35B 278.74M 2026-06
Amarin USD 443.62M 5.8M 2026-06
Amgen USD 11.69B 2.5B 2026-06
Baxter International USD 6.21B 163M 2026-06
Cara Therapeutics USD 14.5M 6.44M 2026-03
Cytokinetics USD -173.49M 653.08M 2026-06
DBV Technologies USD 160.4M 47.5M 2026-06
Eli Lilly USD 33.88B 2.68B 2026-06
Halozyme Therapeutics USD 143.54M 76.09M 2026-06
Intrexon USD 43.17M 75.33M 2024-06
Ionis Pharmaceuticals USD 439.74M 51.68M 2026-06
MannKind USD -67.2M 8M 2026-06
Minerva Neurosciences USD -140.75M 106.17M 2025-12
Nektar Therapeutics USD 576.22M 486.38M 2026-03
Pfizer USD 85.19B 4.91B 2026-06
Rigel Pharmaceuticals USD 117.61M 35.67M 2025-09
United Therapeutics USD 6.4B 499.2M 2026-06
Vanda Pharmaceuticals USD 327.19M 138.81M 2025-12